What a brutal six months it’s been for Regeneron. The stock has dropped 39.3% and now trades at $662.80, rattling many ...

Commonwealth Equity Services LLC reduced its stake in Regeneron Pharmaceuticals by 5.1% in Q4, selling 967 shares and ...

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with ...

The FDA has accepted the resubmitted BLA for linvoseltamab for patients with relapsed/refractory multiple myeloma.

Generali Asset Management SPA SGR has purchased 11,358 shares of Regeneron Pharmaceuticals, valued at approximately $8.1 ...

Type I allergy, an IgE antibody triggered hypersensitivity disease, represents a common public health problem affecting about one third of the world´s population. Upon exposure to allergens, IgE ...

Regeneron Pharmaceuticals Inc. closed 44.49% short of its 52-week high of $1,211.20, which the company reached on August 27th ...

No experience is needed to serve as a judge, usher or registration assistant, event setup and cleanup crew or award ceremony support and activity organizer.

No experience is needed to serve as a judge, usher or registration assistant, event setup and cleanup crew or award ceremony support and activity organizer.

Regeneron Pharmaceuticals Inc. closed 45.10% below its 52-week high of $1,211.20, which the company reached on August 27th.

On March 14, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court for the Northern District of West Virginia’s ...

In the current session, Regeneron Pharmaceuticals Inc. REGN is trading at $672.39, after a 0.89% decrease. Over the past month, the stock decreased by 0.97%, and in the past year, by 30.36%. With ...